At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
octreotide FluidCrystal® injection depotdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR®
In Brief
A Phase 2 clinical trial evaluating octreotide FluidCrystal® injection depot for Acromegaly and Neuroendocrine Tumors. Completed, enrolled 12 participants across 10 sites in 4 countries.
Detailed Summary
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly, Neuroendocrine Tumors
CountriesFrance, Germany, Italy, Sweden
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartJan 2015
Primary CompletionMay 2016
Study CompletionJun 2016
TodayJul 2026
First PostedNov 24, 2014
Enrollment StartJan 1, 2015
Primary CompletionMay 1, 2016
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.6 years ago
Interventions
octreotide FluidCrystal® injection depotdrug